Trial Profile
A Phase 1, Partially Blinded, Placebo-Controlled, study of Intravenously Administered BMS-943539 to assess the pharmacokinetics and in particular the mean T-HALF of BMS-943539 across all doses in healthy male subjects.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2016
Price :
$35
*
At a glance
- Drugs BMS 943539 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 15 Jun 2016 New trial record